CRSP
insider transactionsCRISPR Therapeutics AG — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-3.8K
0 buy · 3.8K sell
Net value · 90d
-$210.6K
$0 in · $210.6K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
1
0 buy · 3.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
25.8K sh
Own New
-
Grant·A
Director
$0
14.7K sh
Own New
-
Grant·A
Director
$0
37.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Grant·A
Director
$0
13.0K sh
Own New
-
Sell·S
Chief Medical Officer
$210.6K
3.8K sh · $55.62
Own -16%
-
Grant·A
General Counsel and Secretary
$0
17.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
22.0K sh
Own New
-
Grant·A
Raju Prasad KEY
Chief Financial Officer
$0
19.5K sh
Own New
-
Exercise·M
Chief Medical Officer
—
10.0K sh
Own +100%
-
Exercise·M
Chief Medical Officer
—
10.0K sh
Own +76%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Ali Behbahani | Grant A | 25.8K | $0 |
| Jun 10, 2026 | Ali Behbahani | Grant A | 14.7K | $0 |
| Jun 10, 2026 | Ali Behbahani | Grant A | 37.0K | $0 |
| Jun 5, 2026 | Simeon George | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Maria Fardis | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Harold Edward Fleming | Grant A | 13.0K | $0 |
| Jun 5, 2026 | John Greene | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Katherine A High | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Sandesh Mahatme | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Briggs Morrison | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Christian Rommel | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Douglas A Treco | Grant A | 13.0K | $0 |
| Jun 5, 2026 | Ali Behbahani | Grant A | 13.0K | $0 |
| May 29, 2026 | Naimish Patel | Sell S | 3.8K | $210.6K |
| May 29, 2026 | James R. Kasinger | Grant A | 17.0K | $0 |
| May 29, 2026 | Naimish Patel | Grant A | 22.0K | $0 |
| May 29, 2026 | Raju Prasad KEY | Grant A | 19.5K | $0 |
| May 28, 2026 | Naimish Patel | Exercise M | 10.0K | — |
| May 28, 2026 | Naimish Patel | Exercise M | 10.0K | — |
About CRSP insider trading
This page tracks insider transactions for CRISPR Therapeutics AG (CRSP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.